Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PBA-0111 Phase 0 in Solid Tumors
NCT06700070Phase 1Recruiting
- Sponsor
- Pure Biologics
- Start
- Mar 2025
- Primary completion
- Dec 2025
- Modality
- Prophylactic Vaccines, Antibody Conjugates, Therapeutic Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of PBA-0111 in head and neck squamous cell carcinoma (HNSCC), soft tissue sarcoma (STS) and triple-negative breast cancer (TNBC), sponsored by Pure Biologics. Primary endpoint: Quantification of Cell Death and Immune Cell Biomarkers by IHC and ISH. Started Mar 2025; status: recruiting.
02
Drugs
PBA-0111
03
Conditions
head and neck squamous cell carcinoma (HNSCC)soft tissue sarcoma (STS)triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT06700070.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06700070.